OBJECTIVES:  Evaluate how response to HER2+ metastatic Breast Cancer (mBC) treatments is associated with healthcare resources utilisation METHODS:  Oncologists (n=204) in UK, Italy, Spain and Netherlands performed a retrospective, independent chart review in 2016. Information was collected from medical records of 1411 patients with HER2+ mBC who progressed after first, second or third treatment (734, 382 and 344 patients). Best response to treatment was either complete or partial (OR, objective response), stable disease (SD) or progressive disease (PD). RESULTS:  During first treatment 97% of patients received targeted therapy (TT). 70% achieved OR, 19% had SD and 11% PD. Patients who achieved OR stayed longer under therapy than those with SD or PD: 13.5 months, 9.3 and 7.1: p≤0.05. During first treatment patients with OR had on average 1.5 consultations per month with an oncologist vs. 1.7 for patients with SD (p≤0.05) and 1.9 with PD (p≤0.05). The number of overnight hospital stays per month was not different according to response: 0.02 stays for patients with OR vs. 0.02 (SD) and 0.04 (PD). Among patients with overnight hospitalization, mean duration of stay was shorter for those with OR compared to SD and PD (0.8 days vs. 1.2 and 1.7 respectively: p≤0.05). The number of imaging studies, PET scans and bone scintigraphies per month of first treatment was lower for patients with OR (0.1, 0.1 and 0.11 respectively for each exam) than those with SD (0.18: p≤0.05, 0.12, 0.12) and PD (0.16, 0.16, 0.15: p≤0.05). This pattern is maintained for further treatments. CONCLUSIONS:  Patients responding to treatment tend to use less healthcare resources per month of treatment than those who do not respond. Achieving a response also leads to longer treatment duration. Targeted therapies in HER2+ mBC are generally associated with higher response rate, longer treatment duration and therefore lower monthly HRU.